Before initiating an SGLT-2 inhibitor, a detailed history should be taken to assess risk factors that might increase the patient’s susceptibility to ketoacidosis and to identify patients at an increased risk of developing DKA, such as patients with reduced residual insulin secretion or type 3 diabetes (e.g., patients with latent autoimmune diabetes in adults (LADA) or a history of pancreatitis) [26,28]. This evidence concerns the gene SLC5A2 and pancreatitis.